Abstracts tagged "autoimmune diseases"

Abstract Number: 0741 • ACR Convergence 2023
Adverse Events Among Patients with and Without Autoimmune Rheumatic Disease Prescribed SGLT2 Inhibitors
Emily G. Oakes¹, Jack Ellrodt¹, May Choi², Jeong Yee¹, Hongshu Guan¹ and Karen Costenbader³, ¹Brigham and Women's Hospital, Boston, MA, ²University of Calgary, Calgary, AB, Canada, ³Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Sodium glucose cotransporter 2 inhibitors (SGLT2i) are oral hypoglycemic agents for Type II diabetes mellitus (T2D) now prescribed for renal and cardiovascular indications. Patients…
Abstract Number: 0962 • ACR Convergence 2023
Topological Proteomic Differences in Fibrotic and Unaffected Skin in Scleroderma
Irene Choi¹, Courtney Yu², Francesco Boin¹, Elizabeth Volkmann³, Stephanie Stanford² and Nunzio Bottini⁴, ¹Cedars-Sinai Medical Center, Los Angeles, CA, ²University of California San Diego, San Diego, CA, ³University of California Los Angeles, Los Angeles, CA, ⁴University of California, San Francisco, CA
Background/Purpose: Scleroderma (SSc) is a chronic autoimmune and rheumatic disease characterized by varying levels of tissue fibrosis in the skin and other internal organs. It…
Abstract Number: 1078 • ACR Convergence 2023
Outcomes of COVID-19 Infection in Hospitalized Autoimmune Patients and Transplant Patients on Immunosuppression
Yashswee KC¹ and Rochella Ostrowski², ¹Loyola University, Oakpark, IL, ²Loyola University Medical Center, Maywood, IL
Background/Purpose: Coronavirus disease 2019 (COVID-19) can have varying outcomes. Patients with chronic conditions or immunosuppression experience more severe illness. Both organ transplant recipients and patients…
Abstract Number: 1329 • ACR Convergence 2023
R851, a Potent Second Generation IRAK1 and IRAK4 Inhibitor Suppresses IL-6 in Vitro and in Vivo for the Treatment of Rheumatoid Arthritis
Yan Chen¹, Sothy Yi¹, Vadim Markovtsov¹, Bhushan Samant¹, Andrew Chow¹, Esteban Masuda¹ and Simon Shaw², ¹Rigel Pharmaceuticals, Inc, South San Francisco, CA, ²Rigel Pharmaceuticals, Inc., South San Francisco, CA
Background/Purpose: The Toll-Like Receptor family (except TLR3) signal through IRAK4 and IRAK1 to produce an array of cytokines (including IL-6, IL-23 and TNFα in response…
Abstract Number: 1586 • ACR Convergence 2023
Keratinocyte VISTA Suppresses Skin IFN-I Production by Regulating DNA Damage Repair and Cytosolic DNA Sensing
Zachary Peters¹, Lindsay Mendyka², Sicong Shan¹, William Rigby³, Christopher Burns⁴, Randolph Noelle⁵ and Sladjana Skopelja-Gardner⁴, ¹Dartmouth College, Hanover, NH, ²Dartmouth Hitchcock, Lebanon, NH, ³Dartmouth-Hitchcock, Norwich, VT, ⁴Dartmouth Hitchcock Medical Center, Lebanon, NH, ⁵Geisel School of Medicine at Dartmouth, Hanover, NH
Background/Purpose: Persistent production of type I interferons (IFN-Is) is one of the hallmarks of lupus skin disease that is exacerbated by ultraviolet (UV) light. We…
Abstract Number: 1755 • ACR Convergence 2023
Unique Pattern of Cadherin 6 Localization in Fibroblast-Like Synoviocytes
Camilla R. L. Machado¹, David Boyle¹, Narayanan B. Perumal², Robert J. Benschop³ and Gary Firestein¹, ¹University of California San Diego, San Diego, CA, ²Eli Lilly and Company, San Diego, CA, ³Eli Lilly and Company, Indianapolis, IN
Background/Purpose: The synovial lining of rheumatoid arthritis (RA) is formed by a network of fibroblast-like synoviocytes (FLS). Cadherins are type I transmembrane proteins and participate…
Abstract Number: 1927 • ACR Convergence 2023
Manifestations, Management and Outcomes of Interstitial Lung Disease Associated with Anti-synthetase Syndrome: A Systematic Literature Review
Koushan Kouranloo¹, Mrinalini Dey², Veronica Yioe³, Lisa G Spencer³ and Caroline V Cotton⁴, ¹Rheumatology & Internal Medicine Trainee- Surrey, UK. Education fellow University of Liverpool, Liverpool, United Kingdom, ²Queen Elizabeth Hospital, London, United Kingdom; University of Liverpool, Liverpool, United Kingdom, ³Liverpool Regional Lung Disease Service, Aintree Hospital, Lower Lane, Liverpool, United Kingdom, ⁴Department of rheumatology, Liverpool University NHS Foundation Trust, Liverpool, United Kingdom
Background/Purpose: Anti-synthetase syndrome (ASS) is a chronic autoimmune inflammatory condition, characterized by myositis, interstitial lung disease (ILD), arthritis, Raynaud's phenomenon and mechanic's hands. This systematic…
Abstract Number: 2057 • ACR Convergence 2023
Medical Trauma and Its Association with Pain and Disability Risk in Children with Inflammatory Arthritis
Leah Medrano¹, Brenda Bursch¹, Jennifer Weiss², Alice Hoftman¹, Joshua Li³, Nicholas Jackson³ and Deborah McCurdy¹, ¹David Geffen School of Medicine, UCLA, Los Angeles, CA, ²Hackensack Meridian School of Medicine, Hackensack, NJ, ³Department of Medicine Statistics Core, David Geffen School of Medicine, UCLA, Los Angeles, CA
Background/Purpose: This study aims to determine the prevalence of medical trauma and its impacts on outcomes in a sample of children with inflammatory arthritis. We…
Abstract Number: 2407 • ACR Convergence 2023
Immuno-permissive Antigen-presenting Cells in Giant Cell Arteritis
Shozo Ohtsuki¹, Chenyao Wang², Ryu Watanabe³, Hui Zhang³, Mitsuhiro Akiyama³, Kenneth Warrington⁴, Gerald J. Berry³, Jorg Goronzy⁴ and Cornelia M. Weyand⁵, ¹Mayo Clinic College of Medicine and Science, Stanford University School of Medicine, Rochester, MN, ²Mayo Clinic College of Medicine and Science, Rochester, MN, ³Stanford University School of Medicine, Stanford, CA, ⁴Mayo Clinic, Rochester, MN, ⁵Mayo Clinic School of Medicine and Stanford University, Rochester, MN
Background/Purpose: Giant cell arteritis (GCA) is a medium and large vessel vasculitis with pathognomonic granulomatous infiltrates in the vessel wall. During the early stages of…
Abstract Number: 2571 • ACR Convergence 2023
Identification of Biomarkers Predicting Steroid Resistance in Immune Checkpoint Inhibitor-Induced Arthritis
Rashmi Thimmapuram¹, Maryam Buni², Huifang Lu³, Jean Tayar⁴, Yuanteng Li⁴, Maria Suarez-Almazor⁵, Rene Rico⁴, Naimah Turner⁴, Roza Nurieva⁴ and Sang Kim⁶, ¹Baylor College of Medicine, Houston, TX, ²MD Anderson Cancer Center, Bellaire, TX, ³UT MD Anderson Cancer Center, Houston, TX, ⁴The University of Texas, MD Anderson Cancer Center, Houston, TX, ⁵MD Anderson Cancer Center, Houston, TX, ⁶The Univesrity of Texas MD Andesron Cancer Center, Pearland, TX
Background/Purpose: Immune checkpoint inhibitors (ICIs) are revolutionizing cancer treatment. However, ICIs often lead to immune-related adverse events (irAEs). Approximately 5% of patients treated with ICIs…
Abstract Number: 0007 • ACR Convergence 2023
Targeting NF-κB Signalling in B Cells from ANCA-associated Vasculitis Impairs B Cell Biology as a Potential Novel Target
Ana Merino-Vico¹, Jan Piet van Hamburg¹, Paul Tuijnenburg¹, Aram Al-Soudi¹, Carlo Bonasia², Boy Helder¹, Abraham Rutgers², Wayel H. Abdulahad², Coen A. Stegeman², Jan-Stephan Sanders², Laura Bergamaschi³, Paul A. Lyons³, Theo Bijma², Laura Van Keep¹, Kirsten wesenhagen¹, Aldo Jongejan¹, Henric Olsson⁴, Niek De Vries¹, Taco W. Kuijpers¹, Peter Heeringa² and Sander Tas⁵, ¹Amsterdam University Medical Centers, Amsterdam, Netherlands, ²University Medical Center Groningen, Groningen, Netherlands, ³University of Cambridge, Cambridge, United Kingdom, ⁴AstraZeneca, Gothenburg, Sweden, ⁵Amsterdam UMC, locatie AMC, Utrecht, Netherlands
Background/Purpose: B cells have gained increased interest in ANCA-associated vasculitis (AAV) research, as the treatment of this autoimmune disease with rituximab (an anti-CD20 B cell…
Abstract Number: 0084 • ACR Convergence 2023
Excess IL-18 Protects from Experimental Autoimmune Encephalomyelitis Mainly via Preferential Augmentation of Suppressor/Regulatory over Autoreactive T-cell Function
Jeremy Morrissette¹, Vinh Dang², Jemy Varghese², Zachary Lanzar¹, Junior Nguyen², Emily Landy³, Anastasia Frank-Kamenetskii⁴ and Scott Canna², ¹University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, ²Children's Hospital of Philadelphia, Philadelphia, PA, ³University of Pittsburgh, Pittsburgh, PA, ⁴CHOP/UPENN, Philadelphia, PA
Background/Purpose: Interleukin 18 (IL-18) is an inflammasome-activated cytokine that canonically amplifies interferon-gamma (IFNg) production and cytotoxicity by CD8 T-cells (CD8Ts) and Th1 CD4 T-cells (CD4Ts).…
Abstract Number: 0201 • ACR Convergence 2023
Tolerability and Safety of Recombinant Zoster Vaccine in Patients with Inflammatory Rheumatic Musculoskeletal Diseases – A Prospective Longitudinal Study over 12 Months
Ioana Andreica¹, Gianna Chierergo², Stefania Reale², Benjamin Wilde³, Styliani Tsiami⁴, David Kiefer⁴, Philipp Sewerin⁴, Hilal Kavruk⁵, Dimitra Karagkiozidou², Barbara Guminski⁴, Andreas Kribben³, Xenofon Baraliakos⁶, Juergen Braun⁴ and Uta Kiltz⁷, ¹Rheumazentrum Ruhrgebiet Herne, Herne, Germany, ²Rheumazentrum Ruhrgebiet, Herne, and Ruhr-Universität Bochum, Herne, Germany, ³Department of Nephrology, University Hospital Essen, University Duisburg-Essen, Essen, Germany, ⁴Ruhr-Universität Bochum and Rheumazentrum Ruhrgebiet, Herne, Germany, ⁵Rheumazentrum Ruhrgebiet, Herne, and Ruhr-Universität Bochum, Düsseldorf, Germany, ⁶Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁷Rheumazentrum Ruhrgebiet, Herne, Germany
Background/Purpose: Herpes zoster (HZ) is common in the elderly, with a lifetime risk of 25%. The primary risk factors for HZ are advanced age and…
Abstract Number: 0302 • ACR Convergence 2023
Remission in Anti-HMGCR Positive Immune-mediated Necrotizing Myopathy Without the Use of Glucocorticoids: A Multicentric Study of 24 Patients
David Martinez-Lopez¹, Cristina Corrales Selaya², Diana Prieto-Peña², Piotr Szczesny³, Antonella Notarnicola⁴, Ricardo Blanco⁵, Ingrid Lundberg⁶ and Maryam Dastmalchi⁶, ¹Hospital de Sierrallana, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Department of Rheumatology, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland; Department of Neurology, Medical University of Warsaw, Warsaw, Poland, ⁴Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, ⁵Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁶Division of Rheumatology, Department of Medicine, Karolinska Institutet; Department of Gastroenterology, Dermatotology, Rhematology, Karolinska Universitetssjukhuset, Stockholm, Sweden
Background/Purpose: Statin-induced immune mediated necrotizing myopathy (IMNM) is a subtype of inflammatory myopathy associated with anti-3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) autoantibodies. This condition is characterized by progressive…
Abstract Number: 0550 • ACR Convergence 2023
Harnessing Machine Learning to Predict Neuropsychiatric Events in Systemic Lupus Erythematosus
Nursen Cetrez¹, Julius Lindblom¹, Raffaele Da Mutten², Dionysis Nikolopoulos² and Ioannis Parodis¹, ¹Karolinska Institutet, Stockholm, Sweden, ²Karolinska Institutet and Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden
Background/Purpose: Neuropsychiatric systemic lupus erythematosus (NPSLE) is linked to increased morbidity, mortality, and adverse health-related quality of life. Early disease, a history of NPSLE, aPL…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].